The Autism Biomarkers Consortium for Clinical Trials: Clinical Characteristics and Interim Evaluation of Clinical Measures Commonly Used in Clinical Trials
S. Faja1, R. A. Bernier2, G. Dawson3, K. Chawarska4, S. Jeste5, C. A. Nelson6, S. J. Webb7, F. Shic8, A. Naples9, C. Sugar10, M. Murias11, J. Dziura12, C. Brandt13 and J. McPartland14, (1)Boston Children's Hospital / Harvard Medical School, Brookline, MA, (2)Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, (3)Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, (4)Child Study Center, Yale University School of Medicine, New Haven, CT, (5)Pediatrics, Children's Hospital Los Angeles, Los Angeles, CA, (6)Department of Developmental Medicine, Boston Children's Hospital, Boston, MA, (7)Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, (8)Center for Child Health, Behavior, and Development, Seattle Children's Research Institute, Seattle, WA, (9)Yale Child Study Center, Yale University School of Medicine, New Haven, CT, (10)Department of Biostatistics, University of California Los Angeles, Los Angeles, CA, (11)Duke Center for Autism and Brain Development, Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, (12)Emergency Medicine, Yale University School of Medicine, New Haven, CT, (13)Yale University, New Haven, CT, (14)Yale Child Study Center, Yale Child Study Center, New Haven, CT